Semaglutide

Updated April 11, 2026

Appetite & Weight Management Fat Loss & Recomp Metabolic Health / Insulin Sensitivity Neuroprotection

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Semaglutide?

If your query is what is semaglutide, the practical answer is: semaglutide is a GLP-1 receptor agonist — a synthetic analog of the human glucagon-like peptide-1 hormone — studied extensively in weight management, type 2 diabetes, and cardiovascular risk reduction contexts.[1][2][3] It is one of the most clinically validated peptide-based compounds in modern medicine.

You may know it better by its brand names: Ozempic (for type 2 diabetes management), Wegovy (for weight management), and Rybelsus (the oral semaglutide formulation). All contain the same semaglutide peptide — the difference is indication, formulation, and approved context. For those asking what is Ozempic: it is simply semaglutide brand name marketed by Novo Nordisk for glycaemic control.

This page should be read alongside the Tirzepatide profile (the most common comparison), the Tirzepatide vs Semaglutide and Liraglutide vs Semaglutide side-by-side comparisons, and the Appetite & Weight Management, Fat Loss & Recomp, and Metabolic Health / Insulin Sensitivity goal pages for broader context.

Compound Profile

Peptide Name

Semaglutide

Brand Names

Ozempic, Wegovy, Rybelsus (Novo Nordisk)

CAS Number

910463-68-2

Molecular Formula

C₁₈₇H₂₉₁N₄₅O₅₉

Molecular Weight

4,113.6 g/mol

Mechanism

Selective GLP-1 receptor agonism (semaglutide GLP-1 / semaglutide GLP 1)

What Does Semaglutide Actually Do?

What does Ozempic do and does semaglutide work are among the most common questions. The evidence is unambiguous: semaglutide produces clinically significant weight reduction and glycaemic improvements in large, well-designed randomised controlled trials.[1][2][3][4]

Useful practical markers from the research include:

• Weight trajectory: the STEP 1 trial demonstrated a mean of approximately 14.9% body weight reduction over 68 weeks versus 2.4% with placebo.[1]
• Appetite regulation: measurable reductions in hunger, food cravings, and energy intake — the core of semaglutide weight loss, semaglutide for weight loss, and Ozempic weight loss mechanisms.[7]
• Glycaemic control: significant HbA1c reductions in type 2 diabetes populations (STEP 2 and SUSTAIN programme).[2]
• Cardiovascular risk reduction: the landmark SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with obesity but without diabetes.[3][8]

Unlike many compounds discussed in peptide research, semaglutide has a depth of human clinical evidence that is exceptional — including multiple Phase III trials, long-term extension data, and regulatory approvals across major markets.

How Semaglutide Works

Understanding how does semaglutide work (or how does Ozempic work / semaglutide mechanism of action) starts with the GLP-1 pathway. Semaglutide mimics the human GLP-1 hormone but with structural modifications that dramatically extend its half-life — allowing once-weekly administration rather than the minutes-long activity of native GLP-1.

The semaglutide mechanism of action involves three interconnected pathways:

• Appetite suppression: GLP-1 receptor activation in the hypothalamus reduces hunger signals and increases satiety, leading to spontaneous caloric reduction.[7]
• Gastric emptying: slowed gastric motility prolongs fullness after meals — a key contributor to the Ozempic weight loss effect.
• Insulin regulation: glucose-dependent insulin secretion is enhanced while glucagon is suppressed, improving glycaemic control without the hypoglycaemia risk seen with some older diabetes treatments.[2]

As a semaglutide GLP-1 agonist, it targets a single receptor pathway — which distinguishes it from dual-agonist compounds like tirzepatide (GIP/GLP-1) and triple-agonist candidates like retatrutide (GIP/GLP-1/glucagon). For a direct mechanism comparison, see Tirzepatide vs Semaglutide.

Appetite & Weight Management Context

This is semaglutide’s primary evidence cluster, anchored to the Appetite & Weight Management goal. The STEP clinical trial programme is the most extensive weight-management dataset for any GLP-1 agonist:

• STEP 1: ~14.9% mean weight loss over 68 weeks in adults with obesity (without diabetes).[1]
• STEP 2: ~9.6% in adults with overweight/obesity and type 2 diabetes — still clinically significant despite the attenuated effect typically seen in diabetic populations.[2]
• STEP 3: ~16% when combined with intensive behavioural therapy.[4]
• STEP 4: demonstrated that continuing semaglutide maintained weight loss, while switching to placebo resulted in regain — raising important questions about long-term use and semaglutide withdrawal symptoms.[5]
• STEP 5: two-year data confirming sustained ~15% weight loss with continued treatment.[6]

The Ozempic weight loss evidence is robust, but context matters: results vary by individual, and weight regain after discontinuation is well-documented. This is a maintenance therapy in current research framing, not a one-off intervention.

Fat Loss & Recomp Context

In the Fat Lost & Recomp context, semaglutide’s evidence is strong for fat mass reduction but raises important body composition questions. The STEP trials report that approximately 60–75% of weight lost is fat mass, with the remainder being lean mass a ratio that has prompted discussion about whether concurrent resistance exercise or protein intake can improve lean mass preservation.

The SELECT trial’s long-term data showed sustained fat loss over 4+ years, with cardiovascular benefits that suggest the fat reduction has meaningful metabolic consequences beyond aesthetics.[3][8] For comparison, tirzepatide trials (SURMOUNT programme) have reported similar or slightly greater fat loss with potentially better lean mass preservation, though head-to-head body composition data remains limited.[9]

Metabolic Health / Insulin Sensitivity Context

Semaglutide’s metabolic impact extends beyond weight, anchored to the Metabolic Health / Insulin Sensitivity goal:

• Glycaemic control: significant HbA1c reductions (1.0–1.8 percentage points) across the SUSTAIN and STEP trial programmes.[2]
• Cardiovascular protection: the SELECT trial — a landmark 17,604-patient RCT — demonstrated a 20% MACE reduction in people with obesity and established cardiovascular disease, but without diabetes. This was the first trial to show cardiovascular benefit from a GLP-1 agonist independent of diabetes status.[3]
• Kidney outcomes: SELECT sub-analysis showed significant reductions in kidney disease progression, suggesting renal protective effects.[10]
• Heart failure: a dedicated trial in HFpEF (heart failure with preserved ejection fraction) showed meaningful improvements in symptoms, physical limitations, and body weight.[11]

The metabolic evidence profile for semaglutide is among the deepest of any peptide-class compound, with outcomes data spanning glycaemic, cardiovascular, renal, and hepatic endpoints. Is Ozempic safe in metabolic contexts? The safety profile is well-characterised across large trials, though individual risk assessment remains important.

Semaglutide Benefits

The most evidence-supported semaglutide benefits include:

• Clinically significant weight reduction: 12–17% mean body weight loss across the STEP programme, sustained over 2+ years with continued use.[1][4][5][6]
• Cardiovascular risk reduction: 20% reduction in major adverse cardiovascular events (SELECT trial) — a benefit independent of diabetes status.[3]
• Glycaemic improvement: meaningful HbA1c reductions in type 2 diabetes, with Ozempic approved for this indication globally.[2]
• Appetite regulation: reduced hunger, cravings, and spontaneous caloric intake via central GLP-1 receptor activation.[7]
• Emerging indications: positive signals in knee osteoarthritis (reduced pain and improved function),[12] heart failure (HFpEF),[11] kidney protection,[10] and potential metabolic-associated fatty liver disease applications.
• Oral formulation available: oral semaglutide (Rybelsus, and newer high-dose 25mg/50mg formulations in trials) provides an alternative to the injectable form, with the OASIS programme showing weight loss approaching that of the subcutaneous formulation.[13][14]

Semaglutide Side Effects

The semaglutide side effects and side effects of semaglutide profile is well-characterised across large clinical trials. For Ozempic side effects and side effects of Ozempic queries: the safety data comes from the same compound across different brand contexts.

Commonly reported issues include:

• Gastrointestinal effects: nausea (most common, typically dose-dependent and often improving over weeks), diarrhoea (semaglutide diarrhoea (semaglutide diarrhea)), vomiting, constipation, and abdominal discomfort. These are the most frequent reason for discontinuation in trials.[1][2][15]
• “Ozempic face”: the widely discussed Ozempic face phenomenon refers to facial volume loss associated with significant overall weight reduction — not a direct pharmacological effect. It occurs with any rapid weight loss and is proportional to the degree of fat mass reduction.[1]
• Gallbladder events: increased incidence of cholelithiasis (gallstones) has been observed, consistent with rapid weight loss from any cause.
• Pancreatitis signals: rare but monitored. Large-scale safety reviews have not confirmed a causal increase above background rates.[15]
• Dental and oral concerns: Ozempic teeth queries relate to anecdotal reports of dental issues, potentially linked to increased gastric acid exposure from GI side effects — though systematic evidence is limited.

For semaglutide long-term side effects (also searched as semaglutide long term side effects) and how long do semaglutide side effects last: the STEP 5 (2-year) and SELECT (4-year) data suggest GI side effects typically attenuate over time, while serious adverse events remain rare and comparable to placebo in long-duration studies.[3][6][15] The question who should not take semaglutide is best addressed by qualified healthcare providers, as contraindications include personal or family history of medullary thyroid carcinoma and MEN2 syndrome.

Half-Life

Semaglutide has an elimination half-life of approximately one week (~168 hours) — which is what enables once-weekly administration and distinguishes it from earlier GLP-1 agonists like liraglutide (half-life ~13 hours, requiring daily administration).

This extended half-life is achieved through structural modifications: a fatty acid side chain that promotes albumin binding, plus amino acid substitutions that resist degradation by dipeptidyl peptidase-4 (DPP-4). The practical result is stable plasma concentrations with minimal peak-trough variation throughout the week.

For how long does semaglutide take to work: appetite effects are typically noticeable within the first weeks, but full weight-loss trajectories in trials developed over 12–20 weeks of titration. Glycaemic improvements can begin earlier.

Limits of Current Evidence

• Weight regain after cessation: the STEP 4 trial clearly demonstrated that discontinuing semaglutide leads to weight regain — raising fundamental questions about duration of use and long-term sustainability.[5]
• Body composition concerns: approximately 25–40% of weight lost may be lean mass. Whether this can be fully mitigated with exercise and nutrition interventions is still being studied.
• Long-term safety beyond 4 years: while the SELECT trial provides 4-year safety data, lifetime exposure data does not yet exist. Semaglutide long-term side effects beyond this window remain partially unknown.
• Cost and access: semaglutide remains expensive, and Ozempic NHS availability and semaglutide UK access vary by region and indication. Supply constraints have been a persistent issue.
• Compounding questions: compounded semaglutide and compounding semaglutide products have emerged during supply shortages, raising quality control and bioequivalence concerns.
• Cancer signals: semaglutide side effects cancer queries reflect ongoing pharmacovigilance, particularly regarding thyroid C-cell tumours observed in rodent studies. Large human safety databases have not confirmed an increased risk, but monitoring continues.[15]
• Comparative positioning: the question is semaglutide the same as Mounjaro (or is Mounjaro semaglutide) reflects public confusion — Mounjaro contains tirzepatide, a different compound with a dual GIP/GLP-1 mechanism. See Tirzepatide vs Semaglutide for the distinction.

Verdict

Semaglutide is the most clinically validated GLP-1 receptor agonist available, with an evidence base spanning multiple Phase III programmes (STEP, SUSTAIN, SELECT, OASIS), regulatory approvals across diabetes and obesity indications, and emerging data in cardiovascular, renal, and osteoarthritis contexts.[1][2][3][12]

Its position in the Appetite & Weight Management space is anchored by effect sizes that were considered unprecedented when STEP 1 reported — though tirzepatide has since demonstrated comparable or greater weight reduction in head-to-head comparisons.[9] The SELECT cardiovascular outcomes data adds a dimension that most weight-management compounds lack entirely.

The critical limitations are sustainability (weight regain on cessation), body composition trade-offs (lean mass loss), and access/cost barriers — particularly relevant for semaglutide UK and Ozempic NHS contexts. For a broader comparison with newer incretin compounds, see the Tirzepatide vs Semaglutide and Liraglutide vs Semaglutide comparison pages, or navigate to the Liraglutide and Retatrutide profiles.

FAQ

What is semaglutide used for?Is semaglutide the same as Ozempic?How does semaglutide work for weight loss? Semaglutide vs tirzepatide: what is the practical difference?

What are the most common semaglutide side effects?What is Ozempic face?Is semaglutide safe long-term?What happens when you stop taking semaglutide?Can you take semaglutide as a tablet?Semaglutide dose and semaglutide dosage: why not listed here?

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. PubMed. (STEP 1)
2. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. PubMed.
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. PubMed. (SELECT)
4. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. JAMA. 2021;325(14):1403-1413. PMID: 33625476. PubMed. (STEP 3)
5. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425. PMID: 33755728. PubMed. (STEP 4)
6. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945. PubMed.
7. Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. PMID: 28266779. PubMed.
8. Lingvay I, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049-2057. PMID: 38740993. PubMed.
9. Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. PMID: 38976257. PubMed.
10. Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. PMID: 38796653. PubMed.
11. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. PMID: 37622681. PubMed.
12. Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. PMID: 39476339. PubMed.
13. Knop FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705-719. PMID: 37385278. PubMed.
14. Aroda VR, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025. PMID: 40934115. PubMed.
15. Singh G, et al. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. PMID: 34305810. PubMed.

PEPTIDEGUIDE.COM

Semaglutide

Evidence ConfidenceHigh

Combined Research Profile

Appetite & Weight Management

8.0/10

Metabolic Health / Insulin Sensitivity

8.0/10

Fat Loss & Recomp

7.5/10

Neuroprotection

5.5/10

Performance Support

5.0/10

How to read this card: scores reflect practical support signal, not guaranteed outcomes.

~7d

Half-life

20

Studies

GLP-1 RA

Class

Sustained

Signal Type

 Research Use Only. Scores reflect practical signal and observed trends, not guaranteed outcomes.

Compound Snapshot

CAS	910463-68-2
Formula	C187H291N45O59
Mass	4114 g/mol
Class	GLP-1 Receptor Agonist

COMPARE PROFILE

Exenatide

EvidenceHigh

Appetite & Weight Management

7.0/10

Metabolic Health / Insulin Sensitivity

7.0/10

Fat Loss & Recomp

6.5/10

Neuroprotection

5.0/10

Performance Support

4.0/10

View Full Comparison →

COMPARE PROFILE

Orforglipron

EvidenceHigh

Appetite & Weight Management

8.0/10

Metabolic Health / Insulin Sensitivity

7.5/10

Fat Loss & Recomp

7.0/10

Longevity / Healthy Aging

4.5/10

Performance Support

3.5/10

View Full Comparison →

COMPARE PROFILE

Retatrutide

EvidenceModerate

Appetite & Weight Management

9.0/10

Fat Loss & Recomp

8.5/10

Metabolic Health / Insulin Sensitivity

8.0/10

Liver / MASLD

8.5/10

Longevity / Healthy Aging

6.0/10

View Full Comparison →

COMPARE PROFILE

Dulaglutide

EvidenceHigh

Appetite & Weight Management

7.5/10

Metabolic Health / Insulin Sensitivity

7.5/10

Fat Loss & Recomp

7.0/10

Neuroprotection

5.0/10

Performance Support

4.5/10

View Full Comparison →

COMPARE PROFILE

Liraglutide

EvidenceHigh

Appetite & Weight Management

8.0/10

Fat Loss & Recomp

7.5/10

Metabolic Health / Insulin Sensitivity

7.5/10

Cardiovascular

7.0/10

Longevity / Healthy Aging

5.5/10

View Full Comparison →

COMPARE PROFILE

Tirzepatide

EvidenceHigh

Appetite & Weight Management

8.5/10

Fat Loss & Recomp

8.0/10

Metabolic Health / Insulin Sensitivity

8.5/10

Neuroprotection

5.0/10

Performance Support

5.0/10

View Full Comparison →

Related Peptides

LiraglutideGLP-1 Receptor AgonistsDulaglutideGLP-1 Receptor AgonistsExenatideGLP-1 Receptor AgonistsDanuglipronGLP-1 Receptor AgonistsOrforglipronGLP-1 Receptor AgonistsTirzepatideDual/Triple Agonists

Medical Disclaimer

The content on PeptideGuide is for informational and educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Always consult a qualified healthcare professional before making health decisions.

About Editorial Policy Contact

© 2026 PeptideGuide · Informational content for research education.

PeptideGuide is an independent research reference. Content is for educational purposes only and does not constitute medical advice. Always consult a qualified professional.